Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PLRX Stock Forecast 2025-2026
$1.31
Current Price
$80.42M
Market Cap
Buy 2
Hold 10
Sell 0
Wall St Analyst Ratings
Distance to PLRX Price Targets
+3,487.8%
To High Target of $47.00
+129.0%
To Median Target of $3.00
+14.5%
To Low Target of $1.50
PLRX Price Momentum
-10.9%
1 Week Change
-3.0%
1 Month Change
-87.8%
1 Year Change
-90.1%
Year-to-Date Change
-91.9%
From 52W High of $16.10
+19.1%
From 52W Low of $1.10
📊 TOP ANALYST CALLS
Did PLRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Pliant is one of their latest high-conviction picks.
Latest PLRX Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, PLRX has a neutral consensus with a median price target of $3.00 (ranging from $1.50 to $47.00). Currently trading at $1.31, the median forecast implies a 129.0% upside. This outlook is supported by 2 Buy, 10 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Eric Joseph at JP Morgan, projecting a 3,487.8% upside. Conversely, the most conservative target is provided by David Lebowitz at Citigroup, suggesting a 14.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PLRX Analyst Ratings
2
Buy
10
Hold
0
Sell
PLRX Price Target Range
Low
$1.50
Average
$3.00
High
$47.00
Current: $1.31
Latest PLRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PLRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 18, 2025 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $0.00 |
| Mar 4, 2025 | Citigroup | David Lebowitz | Neutral | Maintains | $1.50 |
| Mar 4, 2025 | Needham | Joseph Stringer | Hold | Downgrade | $10.00 |
| Mar 4, 2025 | Wells Fargo | Tiago Fauth | Equal-Weight | Maintains | $3.00 |
| Mar 4, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $3.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $0.00 |
| Mar 4, 2025 | Cantor Fitzgerald | Pete Stavropoulos | Neutral | Reinstates | $0.00 |
| Mar 3, 2025 | Leerink Partners | Faisal Khurshid | Market Perform | Downgrade | $2.00 |
| Feb 14, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $10.00 |
| Feb 14, 2025 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $0.00 |
| Feb 10, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Downgrade | $4.00 |
| Feb 10, 2025 | Needham | Joseph Stringer | Buy | Maintains | $10.00 |
| Feb 10, 2025 | Wells Fargo | Tiago Fauth | Equal-Weight | Downgrade | $4.00 |
| Feb 10, 2025 | JP Morgan | Eric Joseph | Neutral | Downgrade | $0.00 |
| Feb 10, 2025 | Citigroup | David Lebowitz | Neutral | Downgrade | $4.00 |
| Feb 10, 2025 | Canaccord Genuity | Edward Nash | Hold | Downgrade | $4.00 |
| Feb 10, 2025 | HC Wainwright & Co. | Ed Arce | Neutral | Downgrade | $0.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $38.00 |
| Sep 13, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $38.00 |
| Sep 9, 2024 | Leerink Partners | Faisal Khurshid | Outperform | Assumes | $33.00 |
Pliant Therapeutics Inc. (PLRX) Competitors
The following stocks are similar to Pliant based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PLRX
Pliant Therapeutics
mkt cap
84.71M
Pliant Therapeutics Inc. (PLRX) Financial Data
Pliant Therapeutics Inc. has a market capitalization of $80.42M with a P/E ratio of -0.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -63.2%.
Valuation Metrics
Market Cap
$80.42M
Enterprise Value
$-165,054,976
P/E Ratio
-0.4x
PEG Ratio
-0.3x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+380.1%
Current Ratio
11.0x
Debt/Equity
23.4x
ROE
-63.2%
ROA
-33.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Pliant Therapeutics Inc. (PLRX) Business Model
About Pliant Therapeutics Inc.
What They Do
Develops therapeutics for treating fibrosis.
Business Model
Pliant Therapeutics Inc. operates within the biotechnology sector, focusing on the development of novel therapeutics designed to treat fibrosis by targeting integrin proteins. The company primarily generates revenue through the advancement of its drug candidates, which are aimed at addressing chronic fibrotic diseases in the lungs and liver, and potentially other organ systems, as they progress through clinical trials and reach the market.
Additional Information
The firm integrates biology, chemistry, and biomolecular engineering in its research, positioning itself as a leader in precision therapies for fibrosis. Its innovative approach not only addresses significant unmet medical needs but also enhances patient quality of life, making it a promising investment opportunity in the biopharmaceutical landscape.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
171
CEO
Dr. Bernard Coulie M.B.A., M.D., Ph.D.
Country
United States
IPO Year
2020
Website
pliantrx.comPliant Therapeutics Inc. (PLRX) Latest News & Analysis
Latest News
Quick Summary
Pliant Therapeutics (Nasdaq: PLRX) presented clinical and preclinical data at the ATS 2025 International Conference from May 16-21, 2025.
Why It Matters
Pliant Therapeutics' presentations at a major conference highlight its ongoing research and development, potentially influencing stock performance and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
1 month ago
Quick Summary
Pliant Therapeutics expects topline data from BEACON-IPF in Q2 2025. A recent workforce realignment aims to extend cash runway for late-stage clinical trials.
Why It Matters
Pliant Therapeutics' strategic realignment and extended cash runway for late-stage trials may enhance its viability, impacting future stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pliant is implementing cost reduction initiatives to better position itself for the execution of late-stage clinical trials.
Why It Matters
Cost reduction initiatives indicate improved efficiency and focus on critical clinical trials, potentially enhancing Pliant's value and attracting investor confidence in its future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pomerantz LLP is investigating claims for investors of Pliant Therapeutics (NASDAQ: PLRX). Interested parties should contact Danielle Peyton at the provided email or phone number.
Why It Matters
The investigation by Pomerantz LLP may indicate potential legal issues for Pliant Therapeutics, which could affect stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pomerantz LLP is investigating claims for investors in Pliant Therapeutics, Inc. (NASDAQ: PLRX). Interested parties should contact Danielle Peyton for more information.
Why It Matters
Pliant Therapeutics faces potential legal scrutiny, which could impact stock performance and investor confidence. Legal investigations often signal underlying issues that may affect financial stability.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Pomerantz LLP is investigating claims for investors of Pliant Therapeutics, Inc (NASDAQ: PLRX). Interested parties should contact Danielle Peyton at the provided email or phone number.
Why It Matters
Investors in Pliant Therapeutics may face legal risks, potentially impacting stock performance and investor sentiment. Legal investigations can signal underlying company issues.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PLRX Stock
What is Pliant Therapeutics Inc.'s (PLRX) stock forecast for 2025?
Based on our analysis of 16 Wall Street analysts, Pliant Therapeutics Inc. (PLRX) has a median price target of $3.00. The highest price target is $47.00 and the lowest is $1.50.
Is PLRX stock a good investment in 2025?
According to current analyst ratings, PLRX has 2 Buy ratings, 10 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.31. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PLRX stock?
Wall Street analysts predict PLRX stock could reach $3.00 in the next 12 months. This represents a 129.0% increase from the current price of $1.31. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pliant Therapeutics Inc.'s business model?
Pliant Therapeutics Inc. operates within the biotechnology sector, focusing on the development of novel therapeutics designed to treat fibrosis by targeting integrin proteins. The company primarily generates revenue through the advancement of its drug candidates, which are aimed at addressing chronic fibrotic diseases in the lungs and liver, and potentially other organ systems, as they progress through clinical trials and reach the market.
What is the highest forecasted price for PLRX Pliant Therapeutics Inc.?
The highest price target for PLRX is $47.00 from Eric Joseph at JP Morgan, which represents a 3,487.8% increase from the current price of $1.31.
What is the lowest forecasted price for PLRX Pliant Therapeutics Inc.?
The lowest price target for PLRX is $1.50 from David Lebowitz at Citigroup, which represents a 14.5% increase from the current price of $1.31.
What is the overall PLRX consensus from analysts for Pliant Therapeutics Inc.?
The overall analyst consensus for PLRX is neutral. Out of 16 Wall Street analysts, 2 rate it as Buy, 10 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are PLRX stock price projections?
Stock price projections, including those for Pliant Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 9:54 AM UTC